See the DrugPatentWatch profile for insulin
Information regarding the specific price of icodec insulin in India is not readily available in the provided context.
When could icodec insulin become available in India?
The timeline for icodec insulin's availability in India depends on regulatory approvals. For instance, Novo Nordisk's long-acting insulin icodec has been submitted for approval in various markets. Data from clinical trials, such as the ONWARDS 6 trial, which compared insulin icodec to insulin glargine U100 in adults with type 2 diabetes, are crucial for these approval processes. The study found that insulin icodec demonstrated comparable glycemic control and a lower rate of severe or medically attended hypoglycemia compared to insulin glargine U100 [1].
What are the advantages of icodec insulin?
Icodec insulin is a novel, once-weekly basal insulin designed to simplify treatment regimens for individuals with diabetes. Its extended dosing interval aims to improve adherence and potentially reduce the burden of daily injections. Clinical studies have indicated favorable outcomes regarding blood glucose management and a reduced risk of hypoglycemia when compared to current daily basal insulins [1].
How does icodec insulin compare to other basal insulins?
Icodec insulin is a once-weekly basal insulin, differentiating it from daily basal insulins like insulin glargine U100. Trials suggest that it achieves similar blood sugar reduction while potentially offering a safety benefit in terms of hypoglycemia. The convenience of a weekly injection schedule is a primary differentiator [1].
Who is developing icodec insulin?
Novo Nordisk is the pharmaceutical company developing icodec insulin [1].
Where can I find information on insulin patent expirations?
DrugPatentWatch.com provides a comprehensive database of drug patents, including information on patent expiry dates for various insulin products and other pharmaceuticals. This resource can be valuable for understanding market exclusivity and the potential for generic or biosimilar entry [2].